Evaxion Biotech A/S
NASDAQ:EVAX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.305
11.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
EVAX
stock under the Base Case scenario is
6.13
USD.
Compared to the current market price of 6.21 USD,
Evaxion Biotech A/S
is
Overvalued by 1%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Evaxion Biotech A/S.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Evaxion Biotech A/S
Balance Sheet Decomposition
Evaxion Biotech A/S
| Current Assets | 18.2m |
| Cash & Short-Term Investments | 14.7m |
| Receivables | 864k |
| Other Current Assets | 2.6m |
| Non-Current Assets | 4.3m |
| PP&E | 3.6m |
| Other Non-Current Assets | 649k |
| Current Liabilities | 5.3m |
| Accounts Payable | 2.5m |
| Other Current Liabilities | 2.8m |
| Non-Current Liabilities | 10.9m |
| Long-Term Debt | 10.7m |
| Other Non-Current Liabilities | 158k |
Free Cash Flow Analysis
Evaxion Biotech A/S
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Evaxion Biotech A/S
|
Revenue
|
7.7m
USD
|
|
Operating Expenses
|
-16.9m
USD
|
|
Operating Income
|
-9.2m
USD
|
|
Other Expenses
|
3.8m
USD
|
|
Net Income
|
-5.4m
USD
|
EVAX Profitability Score
Profitability Due Diligence
Evaxion Biotech A/S's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Evaxion Biotech A/S's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
EVAX Solvency Score
Solvency Due Diligence
Evaxion Biotech A/S's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Evaxion Biotech A/S's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EVAX Price Targets Summary
Evaxion Biotech A/S
According to Wall Street analysts, the average 1-year price target for
EVAX
is 12.58 USD
with a low forecast of 10.1 USD and a high forecast of 16.8 USD.
Dividends
Current shareholder yield for
EVAX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EVAX
stock under the Base Case scenario is
6.13
USD.
Compared to the current market price of 6.21 USD,
Evaxion Biotech A/S
is
Overvalued by 1%.